CINECA IRIS Institutional Research Information System

ROSSO, Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 21.207
NA - Nord America 17.849
EU - Europa 12.510
SA - Sud America 1.584
AF - Africa 549
OC - Oceania 308
Continente sconosciuto - Info sul continente non disponibili 18
Totale 54.025
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.689
CN - Cina 10.613
SG - Singapore 3.367
IT - Italia 2.556
DE - Germania 1.911
JP - Giappone 1.206
FR - Francia 1.127
BR - Brasile 1.100
VN - Vietnam 1.076
GB - Regno Unito 992
SE - Svezia 978
IN - India 937
HK - Hong Kong 842
KR - Corea 821
IE - Irlanda 685
CA - Canada 664
FI - Finlandia 635
ES - Italia 534
TR - Turchia 474
NL - Olanda 452
TW - Taiwan 439
MX - Messico 428
PL - Polonia 385
AT - Austria 347
UA - Ucraina 339
ID - Indonesia 312
AU - Australia 285
RU - Federazione Russa 260
EG - Egitto 248
BE - Belgio 235
DK - Danimarca 199
GR - Grecia 194
IR - Iran 150
AR - Argentina 138
PK - Pakistan 125
RO - Romania 123
IQ - Iraq 107
CH - Svizzera 106
CZ - Repubblica Ceca 104
IL - Israele 100
BD - Bangladesh 86
CO - Colombia 85
PT - Portogallo 85
TH - Thailandia 75
PE - Perù 73
CL - Cile 67
EC - Ecuador 61
SA - Arabia Saudita 58
PH - Filippine 56
MY - Malesia 52
ZA - Sudafrica 51
MA - Marocco 47
UZ - Uzbekistan 37
AE - Emirati Arabi Uniti 34
LT - Lituania 32
NO - Norvegia 31
HU - Ungheria 30
MO - Macao, regione amministrativa speciale della Cina 30
JO - Giordania 28
VE - Venezuela 28
DZ - Algeria 27
HR - Croazia 23
LB - Libano 23
BG - Bulgaria 21
TN - Tunisia 19
NG - Nigeria 18
RS - Serbia 18
SK - Slovacchia (Repubblica Slovacca) 18
NZ - Nuova Zelanda 17
SI - Slovenia 17
ET - Etiopia 16
CM - Camerun 15
GH - Ghana 15
QA - Qatar 15
BY - Bielorussia 14
EU - Europa 14
KE - Kenya 13
MN - Mongolia 13
PY - Paraguay 13
BH - Bahrain 12
AL - Albania 11
AM - Armenia 11
BF - Burkina Faso 11
CY - Cipro 11
GE - Georgia 11
PS - Palestinian Territory 11
AZ - Azerbaigian 10
CR - Costa Rica 10
GT - Guatemala 10
KZ - Kazakistan 10
LY - Libia 10
UY - Uruguay 10
EE - Estonia 9
LK - Sri Lanka 9
LV - Lettonia 9
NP - Nepal 9
OM - Oman 9
LU - Lussemburgo 8
PA - Panama 8
SN - Senegal 8
Totale 53.865
Salva come PNG Salva come JPEG
Città #
Singapore 2.017
Beijing 1.646
Chandler 1.277
Ashburn 1.088
Ann Arbor 986
Shanghai 812
Fairfield 745
Santa Clara 688
Dublin 670
San Jose 664
Guangzhou 608
Houston 498
Tokyo 472
Redwood City 452
Woodbridge 379
Wilmington 363
Los Angeles 357
Nanjing 351
Helsinki 348
Dearborn 347
Hangzhou 340
Seattle 324
Torino 316
Hong Kong 300
Seoul 296
Ho Chi Minh City 273
Villeurbanne 256
Hefei 255
Jacksonville 254
Wuhan 252
Turin 251
Vienna 250
Cambridge 245
Nyköping 237
Ottawa 228
Pisa 224
Taipei 224
Hanoi 222
New York 221
Chengdu 214
Munich 209
Rome 207
The Dalles 202
Medford 201
Columbus 198
Princeton 194
Jinan 191
Lauterbourg 176
Dong Ket 172
Jakarta 170
Warsaw 166
Boston 163
Council Bluffs 161
Dallas 160
Frankfurt am Main 160
Milan 155
Chongqing 154
Changsha 144
Zhengzhou 140
Buffalo 132
London 132
Fremont 127
Central 126
Shenyang 117
Paris 111
Toronto 110
São Paulo 109
San Diego 108
Istanbul 104
Tianjin 102
Amsterdam 98
Sydney 92
Brussels 89
Madrid 89
Nanning 88
Nuremberg 88
Changchun 86
Fuzhou 84
Kunming 82
Bengaluru 81
Washington 80
Chennai 78
Chicago 78
Delhi 78
Boardman 76
Mumbai 74
Cairo 73
New Delhi 72
Shenzhen 70
Central District 69
Berlin 67
Harbin 67
Xi'an 66
Athens 65
Montreal 63
Stockholm 63
Copenhagen 62
Hebei 60
Ankara 59
Newcastle upon Tyne 59
Totale 26.807
Salva come PNG Salva come JPEG
Nome #
Liver cancer: Connections with obesity, fatty liver, and cirrhosis 8.069
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis 6.924
Serum zonulin in patients with inflammatory bowel disease: a pilot study 2.195
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 1.863
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 1.614
Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein. 824
Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease 759
Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. 747
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 654
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study 649
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes 565
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 490
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 453
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 450
Endocrine manifestations of chronic HCV infection 392
Fecal calprotectin: beyond intestinal organic diseases 373
Liver fibrosis: the 2017 state of art 358
Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease 342
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 338
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 303
Physiopathology of intestinal barrier and the role of zonulin 278
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 271
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease 264
Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation 254
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 250
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 246
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease 244
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 238
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 237
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 232
Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic acid breath test 232
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 231
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease 230
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 228
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 225
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease 225
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 223
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 221
Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 220
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 218
Non-alcoholic fatty liver disease and extra-hepatic cancers 218
How to diagnose NAFLD in 2016 217
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 213
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 211
Metabolic Syndrome and Severity of Fibrosis in Nonalcoholic Fatty Liver Disease: An Age-Dependent Risk Profiling Study 209
Diagnosis of Helicobacter pylori infection: a look into molecular aspects of urea breath test 207
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 204
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma 204
Increased epicardial fat and early signs of impaired diastolic and systolic left ventricular function in non-diabetic, non-dyslipidemic, normotensive patients with Nonalcoholic Fatty Liver Disease 203
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis 201
Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in patients with Non Alcoholic Fatty Liver Disease independent of diabetes, hypertension and dyslipidemia 199
Association Between Gut Permeability and Insulin Resistance: Any Role for Zonulin in Patients with Non-Alcoholic Fatty Liver Disease? 199
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 198
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 197
Risk factors for metabolic syndrome after liver transplantation: what has changed over time 192
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 192
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma 191
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 190
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 190
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 188
Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 187
Metabolic handling of an oral fat load in NAFLD patients. 187
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 186
Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification 183
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 180
Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma 175
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology 174
Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with non-alcoholic fatty liver disease 173
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 173
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? 173
Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis 173
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 172
Efficacy of a preparation based on calcium butyrate, bifidobacterium bifidum, bifidobacterium lactis, and fructooligosaccharides in the prevention of relapse in ulcerative colitis: A prospective observational study 171
Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C 170
The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease. 170
Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma 170
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 169
In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease 169
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 168
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease 168
Alteration in lipid metabolism after an oral fat load in patients with NAFLD. 167
Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease 166
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 165
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 165
Altered metabolic profile and adipocyte insulin resistance mark severe liver fibrosis in patients with chronic liver disease 164
Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis 164
After oral fat load NAFLD subjects and healthy controls show different serum free fatty acid trends. 163
Bile acids composition modulate insulin resistance in non-diabetic patients with NAFLD 162
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 157
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 157
A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy 157
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 157
Diagnostic accuracy of soluble sCD163 for the detection of severe fibrosis in patients with Non-Alcoholic Fatty Liver Disease 157
A new index of glutathione turnover (GSH_TI) and its association with severity of non-alcoholic fatty liver disease (NAFLD). 156
Basic and clinical aspects of resistin 156
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 155
Angiopoietin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease 155
Adipose tissue insulin resistance and inflammation, but not reduced hepatic fat oxidation, are associated to active NASH and severe fibrosis. 153
Prevalence of patients with non-alcoholic fatty liver disease: from primary care to tertiary centers. The Turin experience 150
Application of serum cytokeratin-19 fragments (CYFRA 21-1) in predicting the prognosis of patients with hepatocellular carcinoma 149
Totale 43.818
Salva come PNG Salva come JPEG
Categoria #
all - tutte 124.453
article - articoli 0
book - libri 0
conference - conferenze 37.345
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 161.798
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.018 0 0 0 0 0 0 0 0 0 0 434 584
2021/20225.815 297 329 384 504 463 400 568 530 605 457 760 518
2022/20236.210 526 472 299 511 528 1.015 558 441 629 349 409 473
2023/20246.496 595 675 622 586 633 646 461 634 162 440 498 544
2024/20259.368 461 628 593 743 1.422 795 614 606 895 725 843 1.043
2025/202611.614 1.320 749 1.017 1.390 1.383 873 1.821 628 1.308 851 274 0
Totale 55.130